A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

Sickle Cell Disease Clinical Trial

Official title:

A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06198712
• Other study ID #: 4202-HEM-202
• Secondary ID: 2022-001689-36
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: February 7, 2023
• Est. completion date: January 20, 2026

Study information

• Verified date: April 2024
• Source: Novo Nordisk A/S
• Contact: Novo Nordisk
• Phone: (+1) 866-867-7178
• Email: clinicaltrials[@]novonordisk.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to learn about etavopivat, a once a day medicine taken by mouth in adolescents with sickle cell disease. The main goals are to study safety and how long etavopivat stays in the bloodstream, while also studying if there are benefits from taking etavopivat. Eligible participants who enter the study will start a 96-week treatment period. At the end of the 96 weeks, participants will have an end of study visit that occurs 4 weeks later. The participants will receive etavopivat every day throughout the treatment period.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: January 20, 2026
• Est. primary completion date: January 20, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 18 Years

Eligibility

Inclusion Criteria:

• Type of Participant and Disease Characteristics

1. Patient has confirmed diagnosis of SCD

• Documentation of SCD genotype (HbSS, HbSß0-thalassemia or other sickle cell syndrome variants) based on prior history of laboratory testing. Molecular genotyping is not required. SCD genotype may be determined from the results of Hb electrophoresis, high-performance liquid chromatography (HPLC), or similar testing. Note that Hb electrophoresis is performed by the local laboratory at Screening.

2. Hemoglobin greater than or equal to (=) 5.5 and less than (<) 10.5 grams per deciliter (g/dL)

3. Adolescent patients with severe SCD, as defined by at least 1 of the following:

• Two or more VOCs in the past 12 months, defined as a previously documented episode of acute chest syndrome (ACS) or acute painful crisis (for which there was no explanation other than VOC) which required prescription or healthcare professional-instructed use of analgesics for moderate to severe pain
• Hospitalization for any SCD-related complication in the last 12 months
• Proteinuria, defined as an albumin:creatinine ratio (ACR) > 100 milligrams per gram (mg/g) on 2 measures (separated by = 1 month) as an indicator of early renal disease
• History of a conditional TCD in the last 12 months, but not currently being treated with chronic transfusion therapy. Conditional TCD is defined as a TAMMV of 170-199 centimeters per second (cm/s) by TCD or 155-184 cm/s by imaging TCD (TCDi).

4. For participants taking hydroxyurea (HU), the dose of HU (mg/kg) must be stable (no more than a 20% change in dosing) for at least 90 days prior to start of study treatment with no anticipated need for dose adjustments during the study, in the opinion of the Investigator

5. Patients on crizanlizumab or L-glutamine treatment at the time of consent may be

eligible if they:

• Have been on a stable dose for = 12 months at the time of consent (ie, no changes to the dose except for changes to weight or for safety reasons)
• For patients on crizanlizumab, have been = 80% compliant with the planned regimen during the 12 months prior to the time of consent

Exclusion Criteria:

• Medical Conditions

1. More than 10 VOCs within the past 12 months that required a hospital, emergency room (ER), or clinic visit

2. Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days of Screening

3. Abnormal TCD in the prior 12 months Prior/Concomitant Therapy

4. Patients receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion)

5. Received any blood products within 30 days of starting study treatment

6. Receiving or use of concomitant medications that are strong inducers of cytochrome P450 (CYP) 3A4/5 within 2 weeks of starting study treatment

7. Use of voxelotor within 28 days prior to starting study treatment or anticipated need for this agent during the study

8. Receipt of erythropoietin or other hematopoietic growth factor treatment within 28 days of starting study treatment or anticipated need for such agents during the study

9. Receipt of prior cellular based therapy (eg, hematopoietic cell transplant, gene modification therapy)

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease

Intervention

Drug:
• Etavopivat
Participants will receive oral tablets of etavopivat once daily.

Locations

Country	Name	City	State
Canada	The Hospital for Sick Children	On
Kenya	Center For Research In Therapeutic Science	Kisumu
Lebanon	American University of Beirut Medical Center	Beirut
Lebanon	Nini Hospital	Tripoli
United Kingdom	Guys and St Thomas NHS Foundation Trust	Manchester
United Kingdom	Kings College Hospital NHS Foundation Trust	Manchester
United Kingdom	NIHR Manchester Clinical Research facility	Manchester

Sponsors (2)

Lead Sponsor	Collaborator
Forma Therapeutics, Inc.	Novo Nordisk A/S

Countries where clinical trial is conducted

Canada,  Kenya,  Lebanon,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Single-dose: maximum plasma concentration (Cmax)		During the 24-week primary treatment period
Primary	Single-dose: area under the plasma concentration time curve from dosing (time 0) to time t ((AUC)0-t)		During the 24-week primary treatment period
Primary	Single-dose: area under the plasma concentration time curve from zero to time infinity (AUC0-inf)		During the 24-week primary treatment period
Primary	Steady-state maximum plasma concentration (Cmax,ss)		During the 24-week primary treatment period
Primary	Steady-state area under the concentration time curve over the dosing interval (AUCtau,ss)		During the 24-week primary treatment period
Primary	Steady-state average plasma concentration (Cavg,ss)		During the 24-week primary treatment period
Primary	Steady-state minimum plasma concentration (Cmin,ss)		During the 24-week primary treatment period
Primary	Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs related to etavopivat		During the 24-week primary treatment period
Primary	Number of premature discontinuations		During the 24-week primary treatment period
Primary	Number of dose interruptions		During the 24-week primary treatment period
Primary	Number of dose reductions		During the 24-week primary treatment period
Secondary	Incidence of AEs, SAEs, and AEs related to etavopivat		During the 72-week treatment extension period
Secondary	Number of premature discontinuations		During the 72-week treatment extension period
Secondary	Number of dose interruptions		During the 72-week treatment extension period
Secondary	Number of dose reductions		During the 72-week treatment extension period
Secondary	Hemoglobin (Hb) response rate		Baseline, week 12 and 24
Secondary	Change in Hb from baseline		Baseline, week 12 and 24
Secondary	Change from baseline in number of vaso-occlusive crises (VOCs)		Baseline and week 24
Secondary	Change from baseline in Annualized Rate of VOC		Baseline and week 24
Secondary	Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale	PROMIS is a 10-item patient-reported health outcome measurement system used to evaluate quality of life in both children and adults. The assessment is based on the responses - 1. Never, 2. Almost never, 3. Sometimes, 4. Often and 5. Almost always. 'Never' response on the PROMIS fatigue scale indicates better quality of life.	Baseline, week 12 and 24
Secondary	Change from baseline in time-averaged mean of the maximum velocity (TAMMV) by transcranial Doppler ultrasonography (TCD)		Baseline, week 24, 48, and 96